Quince Therapeutics (NASDAQ:QNCX) Releases Quarterly Earnings Results, Beats Estimates By $0.71 EPS

Posted by Brian Himes on May 13th, 2026

Quince Therapeutics (NASDAQ:QNCX – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($1.30) by $0.71, Zacks reports.

Quince Therapeutics Stock Performance

Quince Therapeutics stock traded down $0.02 during trading on Wednesday, reaching $1.24. The company had a trading volume of 355,231 shares, compared to its average volume of 7,298,332. The firm has a market capitalization of $20.15 million, a price-to-earnings ratio of -0.12 and a beta of 1.45. Quince Therapeutics has a 12-month low of $0.80 and a 12-month high of $45.50. The stock’s 50 day moving average price is $1.15 and its two-hundred day moving average price is $14.82.

Hedge Funds Weigh In On Quince Therapeutics

A number of large investors have recently modified their holdings of the company. Nantahala Capital Management LLC increased its position in Quince Therapeutics by 21.6% during the 3rd quarter. Nantahala Capital Management LLC now owns 3,073,729 shares of the company’s stock worth $5,010,000 after purchasing an additional 545,427 shares in the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in Quince Therapeutics during the fourth quarter valued at approximately $7,538,000. Vanguard Group Inc. grew its stake in Quince Therapeutics by 21.3% during the third quarter. Vanguard Group Inc. now owns 1,763,387 shares of the company’s stock worth $2,874,000 after buying an additional 309,349 shares during the period. Millennium Management LLC increased its position in shares of Quince Therapeutics by 1,152.9% in the third quarter. Millennium Management LLC now owns 1,386,776 shares of the company’s stock worth $2,260,000 after acquiring an additional 1,276,094 shares in the last quarter. Finally, Almitas Capital LLC increased its position in shares of Quince Therapeutics by 88.0% in the fourth quarter. Almitas Capital LLC now owns 930,134 shares of the company’s stock worth $3,116,000 after acquiring an additional 435,356 shares in the last quarter. 30.75% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Citizens Jmp cut Quince Therapeutics from a “market outperform” rating to a “market perform” rating in a report on Friday, January 30th. Wall Street Zen upgraded Quince Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday. lowered Quince Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 29th. Maxim Group downgraded shares of Quince Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. Finally, Lucid Cap Mkts lowered shares of Quince Therapeutics from a “strong-buy” rating to a “strong sell” rating in a research report on Friday, January 30th. Five equities research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Reduce” and an average price target of $65.00.

View Our Latest Research Report on QNCX

Quince Therapeutics Company Profile

(Get Free Report)

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.